source
- T-Therapeutics secures $133M Series B to advance TCR-CD3 bispecifics with major pharma investorsT-Therapeutics announced a $133 million Series B financing round backed by several of the world’s largest drug developers, including Eli Lilly, Johnson & Johnson, Merck KGaA and Sanofi, along with…
- Neurocrine launches new safety study after another death linked to Prader-Willi drug VykatNeurocrine Biosciences announced it will start a new study to evaluate dosing and safety of its rare disease drug Vykat in patients with Prader-Willi syndrome who have complex health issues. The m…